From The
Stage

Expert perspectives focused on the latest bioanalytical topic & trends
Male nurse administering shot to old female patient

Noninvasive Liquid Biopsy Assays Integrating Tumor and Immune Biomarkers Prove to Be Promising Tools in Immuno-Oncology

Tumor tissue biopsies have been the traditional method of identifying and analyzing cancer cells. But in addition to being invasive and risky, they have many limitations. Tumor accessibility is often problematic as are issues with monitoring the progression of disease. Tissue samples from a single location don’t always provide a full picture of a tumor’s genetic heterogeneity, limiting accuracy. The more data oncologists have about a patient’s cancer, including genetic

Read More »
Evaluation of CAR T-Cell Therapy Toxicities

Evaluation of CAR T-Cell Therapy Toxicities by Measurement of Cytokines During Therapy

T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.

Read More »
Immuno-oncology in 2018 to revolutionize cancer treatment

Immuno-oncology in 2018: Overcoming Challenges to Revolutionize Cancer Treatment

Many immuno-oncology therapies are seeing success and showing promise for the future, including CAR-T cells, tumor-infiltrating lymphocytes (TILs), checkpoint inhibitors, and natural killer cell therapies. However, there are still many challenges (e.g. cytokine release syndrome in CAR-T therapies) that we as scientists must deal with when working in this new arena of drug development.

Read More »

CAR T-Cell Therapy: Changing the Way Cancer is Treated

One of the most promising types of immunotherapy uses adoptive cell transfer (ACT). While all types of ACT are in their early days of development relatively speaking, one method showing great potential is chimeric antigen receptor T-cell therapy, or CAR-T.

Read More »

Immuno-oncology: Advancing Therapeutic Options for Treating Human Cancers

The clinical landscape for cancer is currently undergoing an exciting shift. Treatment based around generic chemotherapies may be taking a back seat to a host of new, targeted therapies as scientists and doctors are beginning to leverage patients’ own immune systems to eliminate cancer cells – and finding success. While the treatment of cancer by immunological tools can be traced back to the early 1900s, recent advancements in assay methods

Read More »

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.